Patent of the Month: Advancing Continuous Glucose Monitoring
Dexcom, Inc. (website: https://www.dexcom.com) has recently patented a significant advancement in medical device technology. The invention, detailed under Patent Number 12,697,049, is titled “Continuous glucose monitors and related sensors utilizing mixed model and bayesian calibration algorithms.” The dedicated inventors behind this development are Stephen J. Vanslyke, Giada Acciaroli, Martina Vettoretti, Andrea Facchinetti, and Giovanni Sparacino. This patent introduces a sophisticated method for monitoring blood glucose levels by receiving time-varying electrical signals from an analyte sensor and applying dynamic calibration models during specific temporal phases of a monitoring session.
The innovation lies primarily in the application of mixed models and Bayesian calibration algorithms to continuous glucose monitors. Traditional glucose monitoring systems often struggle with sensor drift and signal noise, which can compromise the accuracy of blood glucose estimates. By selecting from a plurality of calibration models and dynamically estimating calibration parameters based on real-time electrical signals, this invention allows the device to adapt to physiological and environmental changes. This results in a highly accurate estimation of the user’s blood glucose level, reducing the need for manual finger-prick calibrations and minimizing the risk of false clinical readings.
September 2026 Industry Recognition
For the month of September 2026, this invention was awarded the patent of the month for the pharma-medical-devices-healthcare industry. This recognition highlights the industry’s shift toward incorporating advanced data science into patient care. Dexcom’s use of Bayesian algorithms represents a critical milestone in diagnostic reliability. The award committee recognized that improving the algorithmic foundation of continuous glucose monitors directly addresses a major clinical challenge in diabetes management. By enhancing predictive accuracy and lowering the margin of error, this technology sets a new standard for algorithmic diagnostics in the medical device sector.
Eligibility for US R&D Tax Credits
The practical applications of this patent present strong opportunities for claiming the Research and Development Tax Credit in the United States. Developing and integrating Bayesian calibration algorithms into medical device firmware requires systematic experimentation to resolve complex technological uncertainties. Activities such as designing prototype algorithms, conducting clinical trials to validate the accuracy of the mixed models against established baseline measurements, and refining the sensor software to process time-varying electrical signals efficiently all qualify as eligible research activities under Section 41 of the US tax code. Furthermore, the iterative testing required to ensure these continuous glucose monitors meet stringent FDA regulatory standards involves significant engineering and software development efforts, making the associated financial investments highly suitable for R&D tax incentives.
